Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib versus placebo after gemcitabine-platinum failure in advanced cholangiocarcinoma
2012-005626-30Phase 2Completed
- Sponsor
- Erasmus Hospital
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cholangiocarcinoma (CCA), gallbladder cancer and biliary cancer comparing Regorafenib + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Median progression-free survival. Started Nov 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerbiliary cancer
Beyond the preview
Go deeper on 2012-005626-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005626-30.